News | May 13, 2025
Bliss GVS Pharma posts Q4 FY25 consolidated PAT at Rs. 15.53 Cr
The company has posted net profit of Rs. 84.29 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 84.29 crores for the Financial Year ended March 31, 2025
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
The restructuring aims to create synergies across the business and strengthen capital structure
The company has reported total income of Rs. 164.63 crores during the period ended June 30, 2023
The company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection
The company has reported total income of Rs. 187.75 crores during the period ended March 31, 2023
The observations are procedural in nature
The company has reported total income of Rs. 211.36 crores during the period ended December 31, 2022
The company had filed a suit in the High Court of Justice, Ghana
Subscribe To Our Newsletter & Stay Updated
